In preparation for the planned IPO of Siemens Healthineers AG, Siemens has nominated nine members, four of whom are independent, to the Supervisory Board of Siemens Healthineers AG. The following individuals will represent Siemens on the Supervisory Board:
- Norbert Gaus, Head of the Research and Technology Center, Siemens AG, as Deputy Chairman
- Andreas C. Hoffmann, Head of Legal and Compliance, Siemens AG
- Michael Sen, Member of the Managing Board of Siemens AG, as Chairman
- Nathalie von Siemens, Managing Director of the Siemens Stiftung and member of the Supervisory Board of Siemens AG
- Ralf P. Thomas, Member of the Managing Board of Siemens AG
The following independent members have been nominated:
- Marion Helmes, Vice Chairwoman of the Supervisory Board of ProSiebenSat1 Media SE, Munich, Germany and Chairwoman of the Audit Committee, Bilfinger SE, Mannheim, Germany
- Philipp Rösler, CEO of the Hainan Cihang Foundation, New York and former German Vice Chancellor and Health Minister
- A. Gregory Sorensen, Executive Chairman of the Board of Directors of IMRIS Corporation, Minnetonka, Minnesota/USA and former CEO of Siemens Healthcare North America
- Karl-Heinz Streibich, Chairman of the Managing Board, Software AG and member of the Supervisory Board of Deutsche Telekom AG, Bonn, Germany
“The nine members of the Supervisory Board have many years of management and leadership experience as well as broad expertise in the fields of medicine, healthcare systems, software, digitalization and finance. It is a strong team to oversee Siemens Healthineers AG. It will support the executive management in attaining the goals they have set for the company and advise them on implementing the Healthineers Strategy 2025”, said Michael Sen, member of the Managing Board of Siemens AG and designated Chairman of the Supervisory Board of Siemens Healthineers AG. “At the same time, we are sending a signal that independent shareholder representatives will have an audible voice on the Supervisory Board of Siemens Healthineers AG.”
Siemens Healthineers is the separately managed Healthcare business of Siemens AG. The company helps healthcare providers throughout the world achieve better results at lower costs by helping them expand precision medicine, transform healthcare, improve the patient’s experience and digitalize healthcare. As a leading medical engineering company, Siemens Healthineers is constantly optimizing its portfolio of products and services, including the core areas of imaging for diagnosis and therapy, laboratory diagnostics and molecular medicine. In addition, the company is constantly optimizing its offerings in the areas of digital healthcare services and hospital management, in collaboration with operators. In its 2017 fiscal year, which ended on September 30, 2017, Siemens Healthineers generated revenues of EUR 13.8 billion and a profit of EUR 2.5 billion, and has approximately 48,000 employees worldwide. You can find additional information at www.siemens.com/healthineers.
These materials are not for distribution, directly or indirectly, in or into the United States (including its territories and possessions, any State of the United States and the District of Columbia), Australia, Canada or Japan. These materials do not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States, Australia, Canada or Japan. The shares mentioned herein have not been, and will not be, registered under the US Securities Act of 1933, as amended (the “Securities Act). The shares may not be offered or sold in the United States, except pursuant to an exemption from the registration requirements of the Securities Act. There will be no public offer of the shares in the United States.
This communication is only being distributed to and is only directed at (i) persons who are outside the European Economic Area or (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). The Shares are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such Shares will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.
This document is not a prospectus for the purposes of Directive 2003/71/EC, as amended by Directive 2010/73/EU, (the “Prospectus Directive”) and as such does not constitute an offer to sell or the solicitation of an offer to purchase shares of Siemens Healthineers AG. Investors should not subscribe for any shares referred to in this document except on the basis of the information contained in the prospectus relating to the shares. A prospectus will be published and investors will be able to obtain a copy of it from Siemens Healthineers AG, Henkestrasse 127, 91052 Erlangen, Germany, or on the Siemens Healthineers AG website.
In any EEA Member State other than Germany and Luxembourg that has implemented the Prospectus Directive, this communication is only addressed to and is only directed at “qualified investors” in that Member State within the meaning of Article 2(1)(e) of the Prospectus Directive.
This communication contains forward-looking statements. These statements are based on the current views, expectations, assumptions and information of the management of Siemens Healthineers AG. Forward-looking statements should not be construed as a promise of future results and developments and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those described in such statements. Siemens Healthineers AG does not assume any obligations to update any forward-looking statements.